# CIONIC

> CIONIC develops prescription wearable neurotechnology for adults with walking difficulties linked to neurological conditions. Its Neural Sleeve 2 combines movement sensing, adaptive electrical stimulation, an app and remote mobility support to assist walking and address muscle spasms. The US-focused company was founded by Jeremiah Robison in 2018 after his daughter’s cerebral palsy diagnosis.

- **Founded:** 2018
- **Headquarters:** San Francisco, United States
- **Founders:** Jeremiah Robison (Founder and CEO)
- **Products:** Cionic Neural Sleeve, Cionic Neural Sleeve 2, Cionic App and Mobility Specialist Support
- **Notable:** First Neural Sleeve received FDA clearance in 2022; shipments began in early 2023., NS-200 FDA 510(k) clearance K243828, May 2, 2025., 2024 company-funded gait publication analyzed 32 participants and reported improved ankle kinematics with stimulation.

## Products & services

- **Cionic Neural Sleeve** — First-generation prescription leg wearable combining movement sensing and adaptive functional electrical stimulation; commercial shipments began in 2023.
- **Cionic Neural Sleeve 2** — Second-generation wearable using MultiStim to combine motor and sensory stimulation, with support for quadriceps, hamstrings, shin and calf. FDA clearance dated May 2, 2025; public launch announced September 23, 2025.
- **Cionic App and Mobility Specialist Support** — Companion app, personalized configuration, training programs and remote onboarding and follow-up.

## Achievements

- First Neural Sleeve received FDA clearance in 2022; shipments began in early 2023.
- NS-200 FDA 510(k) clearance K243828, May 2, 2025.
- 2024 company-funded gait publication analyzed 32 participants and reported improved ankle kinematics with stimulation.
- TIME Best Inventions recognition in 2023; Neural Sleeve 2 received a Special Mention in 2025.
- 2023 Dezeen design project of the year and health and wellbeing product design awards.
- Approximately $35 million total funding reported in company fact sheet.
- Named to Fast Company’s Most Innovative Companies 2026 list, medical device sector.

## Latest updates

- **2026-09** — On September 9, CIONIC announced TRANSFORM, designed to follow 1,000 adults for 12 months through quality-of-life surveys. Early results from 60 first follow-ups are preliminary company-reported observations, not completed trial results.
- **2026-03** — CIONIC announced inclusion in Fast Company’s Most Innovative Companies 2026 list, in the medical device sector.
- **2026-01** — CIONIC’s news index announced research exploring wearable neurotechnology and gait data in Parkinson’s disease; this is research rather than an established treatment claim.
- **2026-01** — CIONIC-affiliated researchers posted a stride-length prediction preprint on medRxiv on January 27; it is not peer-reviewed evidence.
- **2025-12** — Gait metric validation study NCT06503354 completed with 29 participants; registry last updated December 18, with no results posted in the reviewed record.
- **2025-10** — Neural Sleeve 2 recognized with a Special Mention in TIME’s Best Inventions 2025.
- **2025-09** — Public announcement of Neural Sleeve 2 launch following May FDA clearance.

## Links

- Website: https://www.cionic.com/
- LinkedIn: https://www.linkedin.com/company/cionic/
- Twitter/X: https://twitter.com/cionicwear
- YouTube: https://www.youtube.com/@cionicwear
- Instagram: https://www.instagram.com/cionicwear/
- Facebook: https://facebook.com/cionicwear

---

Profile page: https://yespress.io/cionic
Published by YesPress — https://yespress.io
Last updated: 2026-09-30